Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. (not Canton Strategic Holdings, Inc.) on November 27, 2023. The registrant is a Delaware corporation with its principal executive offices in Bridgewater, NJ. The filing reports on a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a clinical development milestone rather than financial performance.
Material Changes
The material event reported is the announcement of positive Phase 1 data for the company's proprietary transmucosal buccal film, TH104. The product is described as a film that easily adheres to the inside of the mouth. No financial changes or comparative period data are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the press release attached as Exhibit 99.1, which details the positive clinical data. The filing does not contain specific forward-looking guidance, risk factors, contingencies, or unusual items beyond the clinical announcement.
Investor Verification Checklist
- Verify the full details of the Phase 1 data for TH104 in the attached press release (Exhibit 99.1).
- Confirm the company name is Tharimmune, Inc. (Ticker: THAR), as the input metadata referenced a different entity.
- Review subsequent filings for financial impact or updated clinical trial timelines.